Jaguar Health develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs.
Cantor Fitzgerald just started coverage with a large $5 price target, which tops the $4.50 consensus target. The last trade to hit the tape Friday was reported at $1.65 up almost 5%.
This company is producing solid revenue and is a great idea for aggressive traders. Lantronix Inc. (NASDAQ: LTRX) provides software as a service (SaaS), engineering services and hardware for edge computing, the Internet of Things (IoT) and remote environment management in the Americas, Europe and elsewhere.
The company’s products include IoT Connectivity, which provide wired and wireless connections that enhance the value and utility of modern electronic systems and equipment through secure network connectivity, application hosting, protocol conversion, secure access for distributed IoT deployments and various other functions. Its SaaS platform enables customers to deploy, monitor, manage and automate across their global deployments through a single platform login.
The company offers its products through value added resellers, systems integrators, distributors, online retailers and original equipment manufacturers, as well as an e-commerce site for direct sales.
The $6.50 Needham target price is lower than the $7.33 consensus figure. Fridays last trade came in at $5.59 up almost 5%.
9 Meters Biopharma
This is another micro-cap biotech that could be a higher winner. 9 Meters Biopharma Inc. (NASDAQ: NMTR) a clinical-stage biopharmaceutical company focused on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases or unmet needs.
The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease. Its NM-002 is a long-acting glucagon-like peptide-1 receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and orphan indications. 9 Meters Biopharma has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002.
BMO Capital Markets started coverage this week with a huge $5 price target. The consensus target is $4.50. The shares were last seen Friday at $1.19.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.